康缘药业(600557) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,028,314,291.81, representing a 26.25% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥70,217,175.01, an increase of 47.48% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥61,245,927.71, reflecting a 38.70% increase compared to the previous year[5]. - Total operating revenue for the first three quarters of 2022 reached CNY 3,125,491,631.19, an increase of 21% compared to CNY 2,583,608,207.75 in the same period of 2021[22]. - Net profit for the third quarter of 2022 was CNY 283,974,013.13, up 35% from CNY 210,413,540.55 in the third quarter of 2021[24]. - Basic earnings per share for Q3 2022 were CNY 0.49, up from CNY 0.36 in Q3 2021, indicating a 36% increase[26]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥6,153,703,406.73, a 2.25% increase from the end of the previous year[6]. - The total assets of the company as of September 30, 2022, were RMB 6,153,703,406.73, compared to RMB 6,018,019,235.83 at the end of 2021, marking a growth of about 2.2%[18]. - The total liabilities decreased to CNY 1,393,009,092.14 in Q3 2022 from CNY 1,545,298,934.37 in Q3 2021, a reduction of approximately 10%[21]. - The company's total equity increased to CNY 4,760,694,314.59 in Q3 2022, compared to CNY 4,472,720,301.46 in Q3 2021, reflecting a growth of about 6%[21]. Cash Flow - The company reported a cash flow from operating activities of ¥612,508,012.74 for the year-to-date, a decrease of 10.37% compared to the previous year[5]. - Cash flow from operating activities for the first three quarters of 2022 was CNY 3,506,264,851.49, compared to CNY 3,223,675,434.45 in the same period of 2021, marking an increase of 9%[26]. - The net cash flow from operating activities for Q3 2022 was CNY 612,508,012.74, a decrease of 10.4% compared to CNY 683,361,113.13 in Q3 2021[27]. - Total cash inflow from operating activities reached CNY 3,662,711,565.24, up 8.7% from CNY 3,367,959,216.39 in the same period last year[27]. - Cash outflow from operating activities was CNY 3,050,203,552.50, an increase of 13.6% compared to CNY 2,684,598,103.26 in Q3 2021[27]. Shareholder Information - The company has a total of 30,074 common shareholders at the end of the reporting period[9]. - The largest shareholder, Jiangsu Kangyuan Group Co., Ltd., holds 30.14% of the shares[9]. Research and Development - Research and development expenses for the first three quarters of 2022 amounted to CNY 437,120,488.39, representing a 30% increase from CNY 336,806,040.18 in the same period of 2021[22]. Inventory and Receivables - The company's inventory decreased to RMB 236,822,438.27 from RMB 338,077,195.06, reflecting a decline of approximately 30%[16]. - Accounts receivable rose to RMB 768,709,052.89, up from RMB 732,061,053.66, indicating an increase of approximately 5%[16]. Financial Management - The company reported a financial expense of CNY -5,239,101.37 in the first three quarters of 2022, a significant improvement compared to CNY 7,282,044.93 in the same period of 2021[22]. - The net cash flow from investing activities was -CNY 195,128,177.52, an improvement from -CNY 233,639,277.64 in Q3 2021[27]. - The net cash flow from financing activities was -CNY 168,289,256.11, an improvement from -CNY 438,458,725.39 in the same quarter last year[29].